Norge -
norsk -
Statens legemiddelverk
celebra 100 mg
upjohn eesv - celekoksib - kapsel, hard - 100 mg
Norge -
norsk -
Statens legemiddelverk
celebra 200 mg
upjohn eesv - celekoksib - kapsel, hard - 200 mg
Norge -
norsk -
Statens legemiddelverk
celebrex 200 mg
2care4 aps - celekoksib - kapsel, hard - 200 mg
Norge -
norsk -
Statens legemiddelverk
celebrex 200 mg
orifarm as - celekoksib - kapsel, hard - 200 mg
Norge -
norsk -
Statens legemiddelverk
celebrex 100 mg
orifarm as - celekoksib - kapsel, hard - 100 mg
Norge -
norsk -
Statens legemiddelverk
celebrex 200 mg
2care4 aps - celekoksib - kapsel, hard - 200 mg
Norge -
norsk -
Statens legemiddelverk
celebrex 100 mg
2care4 aps - celekoksib - kapsel, hard - 100 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.